PPARA and obesity disorder: In conclusion, this study indicated that 13-oxo-ODA acts as an agonist for PPARα not only in vitro but also in vivo where it activated hepatic PPARα, resulting in suppresses of obesity-induced plasma and hepatic levels of TG.